408 related articles for article (PubMed ID: 20839895)
1. Role of pramipexole in the management of Parkinson's disease.
Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
Reichmann H; Brecht MH; Köster J; Kraus PH; Lemke MR
CNS Drugs; 2003; 17(13):965-73. PubMed ID: 14533946
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S; Rey MV; Ratti L; Rascol O
Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
14. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
[TBL] [Abstract][Full Text] [Related]
16. The benefits of pramipexole selection in the treatment of Parkinson's disease.
Silindir M; Ozer AY
Neurol Sci; 2014 Oct; 35(10):1505-11. PubMed ID: 25038745
[TBL] [Abstract][Full Text] [Related]
17. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Taravini IR; Larramendy C; Gomez G; Saborido MD; Spaans F; Fresno C; González GA; Fernández E; Murer MG; Gershanik OS
Neuropharmacology; 2016 Feb; 101():576-89. PubMed ID: 25963416
[TBL] [Abstract][Full Text] [Related]
18. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
19. [Pramipexole and Parkinson's disease, an update].
Martínez-Corral M; Kulisevsky J
Rev Neurol; 2008 Jan 1-15; 46(1):49-52. PubMed ID: 18214827
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]